WORLD Israeli drugmaker Teva to pay Oklahoma $85 mn in opioid suit


Israeli drugmaker Teva to pay Oklahoma $85 mn in opioid suit


04:11, May 28, 2019


Israeli drugmaker Teva agreed to pay the US state Oklahoma $85 million to settle a lawsuit accusing it of complicity in the opioid epidemic, which has killed thousands. (Photo: AFP)

Israeli pharmaceutical giant Teva agreed on Sunday to pay the US state of Oklahoma $85 million to settle a lawsuit accusing it of fueling the state's opioid epidemic, Oklahoma's attorney general said.

The announcement comes after Purdue Pharma, maker of the opioid painkiller OxyContin -- a key driver of the crisis responsible for tens of thousands of deaths in the United States -- reached a $270 million settlement with the state in March.

Attorney General Mike Hunter said in a statement the Teva settlement shows Oklahoma's "resolve to hold the defendants in this case accountable for the ongoing opioid overdose and addiction epidemic that continues to claim thousands of lives each year."

The money will be used by the midwestern state to fight the opioid crisis, Hunter said, with an announcement of how exactly it will be spent made in the future.

Meanwhile, another pharmaceutical titan, Johnson & Johnson, is set to go on trial in Oklahoma on Tuesday, with the company facing similar accusations that it aggressively promoted opioid painkillers despite knowing the risks of addiction.

Overdoses from prescription painkillers and heroin -- a last-resort illicit drug for opioid addicts -- exploded over the last 20 years, according to the National Institute on Drug Abuse.

Almost 400,000 people have died from an overdose involving prescription or illicit opioids, according to the Centers for Disease Control and Prevention (CDC).

Pop icon Prince and rocker Tom Petty were among the high-profile victims of the epidemic.

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue